Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierElanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q1 2026 · $1.37BThe company’s own SEC segment disclosure.
- Pet Health$710.0M52%
- Cattle$316.0M23%
- Poultry$230.0M17%
- Swine$96.0M7%
- Contract Manufacturing$19.0M1%
Elanco Animal Health Incorporated (ELAN) reported revenue of $1.37B in Q2 2026 (quarter ended June 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $54M (3.9% of revenue). For the full year FY2025, revenue was $4.71B (+6.2% year on year) and net income −$232M. Its largest product in 2026-Q1 was Pet Health at $710M, 52% of the disclosed total, just ahead of Cattle at 23%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #1 of 28 by Smart Score